155 related articles for article (PubMed ID: 11260084)
1. Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia?
Bachleitner-Hofmann T; Gisslinger B; Grumbeck E; Gisslinger H
Br J Haematol; 2001 Mar; 112(3):783-6. PubMed ID: 11260084
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide: acute promyelocytic leukemia and beyond.
Bachleitner-Hofmann T; Kees M; Gisslinger H
Leuk Lymphoma; 2002 Aug; 43(8):1535-40. PubMed ID: 12400595
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Huan SY; Yang CH; Chen YC
Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
[TBL] [Abstract][Full Text] [Related]
4. In vitro exposure of acute promyelocytic leukemia cells to arsenic trioxide (As2O3) induces the solitary expression of CD66c (NCA-50/90), a member of the CEA family.
Di Noto R; Boccuni P; Costantini S; Dello Russo A; Lo Pardo C; Copia C; Annunziata M; Cimino R; Ferrara F; Del Vecchio L
Tissue Antigens; 1999 Dec; 54(6):597-602. PubMed ID: 10674975
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
Shao W; Fanelli M; Ferrara FF; Riccioni R; Rosenauer A; Davison K; Lamph WW; Waxman S; Pelicci PG; Lo Coco F; Avvisati G; Testa U; Peschle C; Gambacorti-Passerini C; Nervi C; Miller WH
J Natl Cancer Inst; 1998 Jan; 90(2):124-33. PubMed ID: 9450572
[TBL] [Abstract][Full Text] [Related]
6. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system.
Dai J; Weinberg RS; Waxman S; Jing Y
Blood; 1999 Jan; 93(1):268-77. PubMed ID: 9864170
[TBL] [Abstract][Full Text] [Related]
7. Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation.
Rojewski MT; Baldus C; Knauf W; Thiel E; Schrezenmeier H
Br J Haematol; 2002 Mar; 116(3):555-63. PubMed ID: 11849211
[TBL] [Abstract][Full Text] [Related]
8. High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.
Noguera NI; Pelosi E; Angelini DF; Piredda ML; Guerrera G; Piras E; Battistini L; Massai L; Berardi A; Catalano G; Cicconi L; Castelli G; D'Angiò A; Pasquini L; Graziani G; Fioritoni G; Voso MT; Mastrangelo D; Testa U; Lo-Coco F
Oncotarget; 2017 May; 8(20):32550-32565. PubMed ID: 28427227
[TBL] [Abstract][Full Text] [Related]
9. Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance.
Lehmann S; Bengtzen S; Paul A; Christensson B; Paul C
Eur J Haematol; 2001 Jun; 66(6):357-64. PubMed ID: 11488934
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide and promyelocytic leukemia protein-adenovirus synergistically inhibit in vitro and in vivo growth of a hepatoma cell line.
Cui L; Zhang S; Zhang W; Hu Z; Cao Z; Li T
Oncol Res; 2010; 18(7):305-14. PubMed ID: 20377131
[TBL] [Abstract][Full Text] [Related]
11. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
Zhang P
J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
[TBL] [Abstract][Full Text] [Related]
12. The effects of arsenic trioxide (As2O3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages.
Alemany M; Levin J
Leuk Lymphoma; 2000 Jun; 38(1-2):153-63. PubMed ID: 10811458
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside.
Rojewski MT; Körper S; Schrezenmeier H
Leuk Lymphoma; 2004 Dec; 45(12):2387-401. PubMed ID: 15621751
[TBL] [Abstract][Full Text] [Related]
14. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
Zhang T; Westervelt P; Hess JL
Mod Pathol; 2000 Sep; 13(9):954-61. PubMed ID: 11007035
[TBL] [Abstract][Full Text] [Related]
15. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of all-trans retinoic acid resistant and chemotherapy naïve acute promyelocytic patients with arsenic trioxide--two case reports.
Lin CP; Huang MJ; Chang IY; Lin WY
Leuk Lymphoma; 2000 Jun; 38(1-2):191-4. PubMed ID: 10811462
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
19. [Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
Tanaka Y; Komatsu H; Ishii K; Nakamura F; Hayashi T; Sawada H; Ono Y; Imanaka T
Rinsho Ketsueki; 2000 Apr; 41(4):354-7. PubMed ID: 10846468
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
Khaleghian A; Ghaffari SH; Ahmadian S; Alimoghaddam K; Ghavamzadeh A
J Cell Biochem; 2014 Oct; 115(10):1729-39. PubMed ID: 24819152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]